Is ASX 300 healthcare company Incannex profitable?

Is the pharmaceutical company operating with a green balance sheet? Let's take a look.

| More on:
A woman looks quizzical while looking at a dollar sign in the air.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex was one of 16 shares added to the ASX 300 Index in the September rebalance
  • That sees it join many other loss-making ASX 300 shares
  • The company posted an after-tax loss of $14.9 million for financial year 2022, but its cash position is still strong

Healthcare share Incannex Healthcare Ltd (ASX: IHL) was added to the S&P/ASX 300 Index (ASX: XKO) last month.

The company is a clinical-stage pharmaceutical company with a focus on developing medicinal cannabinoid products and psychedelic therapies to help those with unmet medical needs.

Speaking on the company's inclusion in the index, Incanncex CEO and managing director Joel Latham said:

We're delighted to be … listed among the largest and most-recognisable companies in Australia.

Being listed in the index is a precursory investment condition for many domestic and international investment institutions so we are excited for the possibilities this recognition may bring.

But does adding the healthcare share to the ASX 300 expand the index's unprofitable constituents? Let's take a look at the company's balance sheet to find out.

Is ASX 300 healthcare share Incannex profitable?

Healthcare share Incannex is among 16 shares added to the ASX 300 in the September quarterly rebalance. And the company is one of many being included in the rebalance that isn't turning a profit.

Incannex brought in $788,654 of income in financial year 2022. However, that was nowhere near enough to cover the company's costs.

In fact, it wasn't even a third of the company's advertising and investor relations spend – sitting at $2.7 million. Incannex also forked out $5.3 million on research and development and $2 million on employee salaries and benefits.

All in all, the ASX 300 healthcare company posted a total after-tax loss of $14.9 million for financial year 2022.

Though, it ended the period with $37.5 million of cash and no debt, meaning it's not in dire need of capital.

Its cash position was bolstered back in April when it underwent a $24 million options exercise program. Additionally, the company listed on the Nasdaq in March.

Finally, Incannex finalised its acquisition of APIRx Pharmaceuticals in August.

Sadly, the company's productive year hasn't been reflected in its share price's performance.

The stock has fallen 51% in 2022 so far to trade at 32 cents right now, including a 14% gain on Friday. That's 0.6% higher than it was this time last year.

For comparison, the ASX 300 has slumped 11% year to date and 7% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman going for a scan reassured by doctor
Healthcare Shares

How AI could boost this ASX 300 healthcare stock

The Firetrail investment management team see AI providing a 'material tailwind' for this stock.

Read more »

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.
Healthcare Shares

Why is the ResMed share price diving 5% today?

Weight loss wonder drugs are weighing heavily on this stock.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Why is the Telix share price jumping 15% to a record high?

This healthcare stock is scaling new heights on Thursday. But why?

Read more »

Stressed thoughtful old female general practitioner doctor physician looking in distance, considering difficult medical problem solution or illness treatment, working on computer in clinic office.
Healthcare Shares

How much do you need to invest in CSL shares for $8,000 in annual dividends?

CSL's dividends are exponentially more valuable for long-term investors.

Read more »

smiling health care workers in a medical setting
Healthcare Shares

'Critical unmet need': Why everyone is talking about this ASX 200 healthcare stock

This healthcare stock has been given a boost from the US FDA today.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

Why this ASX 200 stock is a retiree's dream

I think this is a very healthy and resilient stock.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »